Biomarkers

Discover all biomarkers in precision medicine

Loading biomarkers...

PIK3CA - Biomarker

Results for "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha"

Target: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. A pseudogene of this gene has been defined on chromosome 22. [provided by RefSeq, Apr 2016]

Clinical Applications

Breast CancerHepatocellular CarcinomaOvarian CancerSomatic Adenocarcinoma of the LungStomach Cancer

ncbi

Approved Therapies

Itovebi (INAVOLISIB) ^[5]

Status: approved

APPROVED

VIJOICE (ALPELISIB) ^[6]

Status: approved

APPROVED

PIQRAY (ALPELISIB) ^[7]

Status: approved

APPROVED

TRUQAP (CAPIVASERTIB) ^[8]

Status: approved

APPROVED

Ibrance (PALBOCICLIB) ^[9]

Status: approved

APPROVED

Ibrance (PALBOCICLIB) ^[10]

Status: approved

APPROVED

Pipeline Therapies

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

MedSIR

PHASE2

Combination of Serabelisib and Insulin Suppressing Diet with or Without Nab-paclitaxel in Subjects with Advanced Solid Tumors with PIK3CA Mutations

Faeth Therapeutics

PHASE1

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Washington University School of Medicine

PHASE2

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Hoffmann-La Roche

PHASE3

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

PHASE2

Companies Working on phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

MedSIR

Breast Cancer

Inavolisib

Faeth Therapeutics

Advanced Solid Tumor

PaclitaxelSerabelisib

Washington University School of Medicine

Breast Neoplasms

AnastrozoleGoserelinPalbociclib

Hoffmann-La Roche

Breast Cancer

FulvestrantInavolisib

TrialsMap

Clinical Intelligence Agent

Interactive Clinical Trials Map

750

Europe

407

United States

362

Asia

275

Other

LitSearch

Scientific Literature Agent

Scientific Publications

PIK3CA-mutations in breast cancer.

PubMedDec 2022

A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.

PubMedJul 2021

Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids.

PubMedJun 2020

Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.

PubMedNov 2019

Frequency and spectrum of PIK3CA somatic mutations in breast cancer.

PubMedMay 2020

Research Insights

Publication count:

5 papers

Research focus:

Breast Cancer

Sources & References

PIK3CA-mutations in breast cancer.

PubMed•Dec 2022

A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.

PubMed•Jul 2021

Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids.

PubMed•Jun 2020

Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.

PubMed•Nov 2019

Frequency and spectrum of PIK3CA somatic mutations in breast cancer.

PubMed•May 2020

Biomarkers

Results for "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha"

Target: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

Clinical Applications

Approved Therapies

Itovebi (INAVOLISIB) [5]

VIJOICE (ALPELISIB) [6]

PIQRAY (ALPELISIB) [7]

TRUQAP (CAPIVASERTIB) [8]

Ibrance (PALBOCICLIB) [9]

Ibrance (PALBOCICLIB) [10]

Pipeline Therapies

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

Combination of Serabelisib and Insulin Suppressing Diet with or Without Nab-paclitaxel in Subjects with Advanced Solid Tumors with PIK3CA Mutations

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Companies Working on phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

MedSIR

Faeth Therapeutics

Washington University School of Medicine

Hoffmann-La Roche

TrialsMap

Interactive Clinical Trials Map

LitSearch

Scientific Publications

PIK3CA-mutations in breast cancer.

A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.

Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids.

Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.

Frequency and spectrum of PIK3CA somatic mutations in breast cancer.

Research Insights

Sources & References

Itovebi (INAVOLISIB) ^[5]

VIJOICE (ALPELISIB) ^[6]

PIQRAY (ALPELISIB) ^[7]

TRUQAP (CAPIVASERTIB) ^[8]

Ibrance (PALBOCICLIB) ^[9]

Ibrance (PALBOCICLIB) ^[10]